Skip to main content
Log in

Serum Sirolimus Levels After Implantation of Third Generation Drug Eluting Cobalt Chromium Coronary Stent in Ductus Arteriosus in Neonates with Duct-Dependent Pulmonary Circulation

  • Original Article
  • Published:
Pediatric Cardiology Aims and scope Submit manuscript

Abstract

Ductal stenting (DS) palliates duct-dependent lesions using coronary stents. Sirolimus-eluting stents have replaced bare-metal stents in coronary interventions. Concerns exist about sirolimus levels in neonates. Therapeutic immunosuppressive sirolimus level is 5–15 ng/ml. After neonatal DS, drug levels were assessed at 24 h, 7 days and monthly thereafter till they were undetectable. Clinical course, ductal patency till their final corrective surgery was analyzed. The exact quantity of sirolimus in each stent was known. Twelve neonates with median age of 5.5 days received sirolimus-eluting stents, one stent in nine and two in the rest. The lesions were pulmonary atresia intact ventricular septum(PAIVS) in four, univentricular lesions with pulmonary atresia in four, biventricular lesions with pulmonary atresia in three and right ventricular rhabdomyoma in one neonate. If single stents up to 22 mm length, 24-h drug levels were less than 5 ng/ml. Even though 24-h levels were above 5 ng/ml in patients with single longer stent or two stents, it reduced to very low levels by seventh day. Two hospital deaths included rhabdomyoma with complete heart block and post-valvotomy cardiac failure for PAIVS. Stent patency after valvotomy for PAIVS exceeded three years. Patency was retained for 8–27 months till their elective corrective surgery in others. Sirolimus levels were acceptable at 24 h in all neonates receiving single stent under 22 mm length. In patients needing two stents, drug levels were in immunosuppressive range at 24 h but reduced rapidly within 7 days. The palliation provided by sirolimus-eluting DS was sufficiently long to provide clinical benefit.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Peters B, Ewert P, Berger F (2009) The role of stents in the treatment of congenital heart disease: current status and future perspectives. Ann Pediatr Cardiol 2:3–23

    Article  PubMed  Google Scholar 

  2. Wells WJ, Yu RJ, Batra AS, Monforte H, Sintek C, Starnes VA (2005) Obstruction in modified Blalock shunts: a quantitative analysis with clinical correlation. Ann Thorac Surg 79:2072–2076

    Article  Google Scholar 

  3. Coe JY, Olley PM (1991) A novel method to maintain ductus arteriosus patency. J Am Coll Cardiol 18:837–841

    Article  CAS  Google Scholar 

  4. Gibbs JL, Uzun O, Blackburn ME, Wren C, Hamilton JR, Watterson KG (1999) Fate of the stented arterial duct. Circulation 99:2621–2625

    Article  CAS  Google Scholar 

  5. Sivakumar K, Bhagyavathy A, Coelho R, Satish R, Krishnan P (2012) Longevity of neonatal ductal stenting for congenital heart diseases with duct dependent pulmonary circulation. Congenit Heart Dis 7:526–533

    Article  Google Scholar 

  6. Costa MA, Simon DI (2005) Molecular basis of restenosis and drug-eluting stents. Circulation 111:2257–2273

    Article  Google Scholar 

  7. Babapulle MN, Eisenberg MJ (2002) Coated stents for the prevention of restenosis: part 1. Circulation 106:2734–2740

    Article  Google Scholar 

  8. Lee KJ, Hinek A, Chaturvedi RR, Almeida CL, Honjo O, Koren G, Benson LN (2009) Rapamycin-eluting stents in the arterial duct: experimental observations in the pig model. Circulation 119:2078–2085

    Article  CAS  Google Scholar 

  9. Mueller GC, Dodge-Khatami A, Weil J (2010) First experience with a new drug eluting balloon for the treatment of congenital pulmonary vein stenosis in a neonate. Cardiol Young 20:455–458

    Article  Google Scholar 

  10. Lobach NE, Pollock-Barziv SM, West LJ, Dipchand AI (2005) Sirolimus immunosuppression in pediatric heart transplant recipients: a single-center experience. J Heart Lung Transplant 24:184–189

    Article  Google Scholar 

  11. Riede FT, Schneider P, Dahnert I (2007) Transient sirolimus levels after implantation of a sirolimus eluting stent in an infant. Clin Res Cardiol 96:508–510

    Article  Google Scholar 

  12. Li SS, Cheng BC, Lee SH (2005) Giant coronary aneurysm formation after sirolimus-eluting stent implantation in Kawasaki disease. Circulation 112:e105–e107

    Article  Google Scholar 

  13. Rashid A, Ringewald J, Saucedo J (2005) Placement of a sirolimus coated stent in the distal left internal mammary artery of an 8-year-old boy. J Invasive Cardiol 17:329–330

    Google Scholar 

  14. Lee KJ, Seto W, Benson L, Chaturvedi RR (2015) Pharmacokinetics of sirolimus eluting stents implanted in neonatal arterial duct. Circ Cardiovasc Interv 8:e002233

    Google Scholar 

  15. Akin I, Schneider H, Ince H, Kische S, Rehders TC, Chatterjee T, Nienabar CA (2011) Second and third generation drug eluting coronary stents: progress and safety. Herz 36:190–196

    Article  CAS  Google Scholar 

  16. Dani S, Costa RA, Joshi H, Shah J, Pandya R, Virmani R et al (2013) First in human evaluation of the novel Biomime sirolimus eluting coronary stent with bioabsorbable polymer for the treatment of single denovo lesions located in native coronary vessels—results from the Merit-1 trial. Eurointervention 9:493–500

    Article  Google Scholar 

  17. Alwi M, Choo KK, Latiff HA, Kandavello G, Samion H, Mulyadi MD (2004) Initial results and medium-term follow-up of stent implantation of patent ductus arteriosus in duct-dependent pulmonary circulation. J Am Coll Cardiol 44:438–445

    Article  Google Scholar 

  18. Boshoff DE, Michel-Behnke I, Schranz D, Gewillig M (2007) Stenting the neonatal arterial duct. Expert Rev Cardiovasc Ther 5:893–901

    Article  Google Scholar 

  19. Schneider M, Zartner P, Sidiropoulos A, Konertz W, Hausdorf G (1998) Stent implantation of the arterial duct in newborns with duct-dependent circulation. Eur Heart J 19:1401–1409

    Article  CAS  Google Scholar 

  20. Benson L, Arsdell GV (2018) Comparisons between ductal stenting and Blalock-Taussig shunts for infants with ductal-dependent pulmonary circulation. Circulation 137:602–604

    Article  Google Scholar 

  21. Bentham JR, Zava NK, Harrison WJ, Shauq A, Kalantre A, Derrick G et al (2018) Duct stenting versus modified Blalock-Taussig shunt in neonates with duct dependent pulmonary blood flow. Circulation 137:581–588

    Article  Google Scholar 

  22. Glatz AC, Petit CJ, Goldstein BH, Kelleman MS, McCracken CE, McDonnell A, Buckey T et al (2018) Comparison between patent ductus arteriosus stent and modified Blalock-Taussig shunt as palliation for infants with ductal-dependent pulmonary blood flow. Circulation 137:589–601

    Article  Google Scholar 

  23. Feltes TF, Bacha E, Beekman RH III, Cheatham JP, Feinstein JA, Gomes AS et al (2011) Indications for cardiac catheterization and intervention in pediatric cardiac disease. Circulation 123:2607–2652

    Article  Google Scholar 

  24. Aggarwal V, Dhillon GS, Penny DJ, Gowda ST, Qureshi AM (2019) Drug-eluting stents compared to bare metal stents for stenting the ductus arteriosus in infants with ductal-dependent pulmonary blood flow. Am J Cardiol 124:952–959

    Article  CAS  Google Scholar 

  25. Abizaid A, Costa JR Jr (2010) New drug-eluting stents. An overview on biodegradable and polymer-free next-generation stent systems. Circ Cardiovasc Interv 3:384–393

    Article  CAS  Google Scholar 

  26. Meier-Kriesche HU, Kaplan B (2000) Toxicity and efficacy of sirolimus: relationship to whole blood concentration. Clin Ther 22(Suppl B):B93–B100

    Article  CAS  Google Scholar 

  27. Qureshi AM, Goldstein BH, Glatz AC, Agrawal H, Aggarwal V, Ligon RA et al (2019) Classification scheme for ductal morphology in cyanotic patients with ductal dependent pulmonary blood flow and association with outcomes of patent ductus arteriosus stenting. Catheter Cardiovasc Interv 93:933–943

    Article  Google Scholar 

  28. Fenton KN, Siewers RD, Rebovich B, Pigula FA (2003) Interim mortality in infants with systemic-to-pulmonary artery shunts. Ann Thorac Surg 76:152–156

    Article  Google Scholar 

Download references

Funding

None.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Kothandam Sivakumar.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Sivakumar, K., Pavithran, S., Sonawane, B. et al. Serum Sirolimus Levels After Implantation of Third Generation Drug Eluting Cobalt Chromium Coronary Stent in Ductus Arteriosus in Neonates with Duct-Dependent Pulmonary Circulation. Pediatr Cardiol 41, 1354–1362 (2020). https://doi.org/10.1007/s00246-020-02381-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00246-020-02381-4

Keywords

Navigation